Treatment of choice for acute severe steroid-refractory ulcerative colitis is remicade

Inflammatory Bowel Diseases

Volumn 15, Issue 1, 2009, Pages 143-145

  Halfvarson, Jonas ^a   Järnerot, Gunnar ^a  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETAMETHASONE; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOSPORIN A; HYDROCORTISONE; INFLIXIMAB; PLACEBO; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; GLUCOCORTICOID; MONOCLONAL ANTIBODY;

ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOKINE RELEASE; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; HYPERTENSION; HYPERTRICHOSIS; INFECTION COMPLICATION; INJECTION SITE REACTION; LONG TERM CARE; LOW DRUG DOSE; NEPHROTOXICITY; PARESTHESIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROCTOCOLECTOMY; RECURRENT DISEASE; RELAPSE; SALVAGE THERAPY; SEIZURE; TREATMENT DURATION; TREATMENT INDICATION; ULCERATIVE COLITIS; ACUTE DISEASE; DRUG RESISTANCE; REVIEW;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; DRUG RESISTANCE; GLUCOCORTICOIDS; HUMANS;

EID: 61949443157     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20782     Document Type: Article

References (26)

1. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut. 1963;4:299-315.
2. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;1041-1048.
3. Truelove SC, Willoughby CP, Lee EG, et al. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet. 1978;2:1086-1088.
4. Järnerot G, Rolny P, Sandberg-Gertzén H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology. 1985;89:1005-1013.
5. Cohen RD, Brodsky AL, Hanauer SB. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflamm Bowel Dis. 1999;5:1-10.
6. Gustavsson A, Halfvarson J, Magnuson A, et al. Long-term colectomy rate after intensive intravenous corticosteroid therapy for ulcerative colitis prior to the immunosuppressive treatment era. Am J Gastroenterol. 2007;102:2513-2519.
7. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330: 1841-1845.
8. Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol. 2005;17: 79-84.
9. Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:760-765.
10. Van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125:1025-1031.
11. Shibolet O, Regushevskaya E, Brezis M, et al. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev. 2005;CD004277.
12. Arts J, D'Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis. 2004;10:73-78.
13. Braegger CP, Nicholls S, Murch SH, et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 1992;339:89-91.
14. Murch SH, Braegger CP, Walker-Smith JA, et al. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut. 1993;34:1705-1709.
15. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;3:CD005112.
16. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001;7:83-88.
17. Seo M, Okada M, Yao T, et al. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol. 1992;87:971-976.
18. Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805-1811.
19. Lindgren SC, Flood LM, Kilander AF, et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol. 1998;10:831-835.
20. Kohn A, Daperno M, Armuzzi A, et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther. 2007;26:747-756.
21. Jakobovits SL, Jewell DP, Travis SP. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment Pharmacol Ther. 2007;25:1055-1060.
22. Gustavsson A, Järnerot G, Hertervig E, et al. A 2-year follow-up study of the Swedish-Danish infliximab trial in steroid resistant acute ulcerative colitis [abstract]. Gastroenterology. 2007;132(Suppl 2).
23. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
24. Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007;204:956 -962; discussion 962-953.
25. Travis S. Infliximab and azathioprine: bridge or parachute? Gastroenterology. 2006;130:1354-1357.
26. Olsen T, Goll R, Cui G, et al. Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis. Scand J Gastroenterol. 2007;42:1312-1320.